HOLON, Israel, March 5, 2019 /PRNewswire/ -- Compugen
Ltd. (NASDAQ: CGEN), a leader in predictive discovery and
development of first-in-class therapeutics for cancer
immunotherapy, today announced that John
Hunter, PhD, Chief Scientific Officer, will present a
corporate overview and update at the Cowen and Company
39th Annual Health Care Conference in Boston, on Monday,
March 11, 2018, at 2:50
PM.
A live webcast of the presentation will be available on
Compugen's website. A replay will be available after the
presentation ends.
About Compugen
Compugen is a therapeutic discovery and development company
utilizing its broadly applicable predictive discovery
infrastructure to identify novel drug targets and develop
first-in-class therapeutics in the field of cancer immunotherapy.
The Company's therapeutic pipeline consists of immuno-oncology
programs against novel drug targets it has discovered, including T
cell immune checkpoints and myeloid target programs. Compugen's
business model is to selectively enter into collaborations for its
novel targets and related drug product candidates at various stages
of research and development. The Company is headquartered in
Israel, with facilities in both
Israel and South San Francisco, CA. Compugen's shares are
listed on NASDAQ and the Tel Aviv Stock Exchange under the ticker
symbol CGEN. For additional information, please visit Compugen's
corporate website at www.cgen.com.
Company contact:
Elana
Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972(3)765-8124
Investor Relations contact:
Burns McClellan, Inc.
Jill Steier
Email: jsteier@burnsmc.com
Tel: 212-213-0006
View original
content:http://www.prnewswire.com/news-releases/compugen-to-present-at-the-cowen-and-company-39th-annual-health-care-conference-300806583.html
SOURCE Compugen Ltd.